A promising new COVID-19 vaccine candidate developed by researchers at the Centenary Institute and the University of Sydney ...

Combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

COVID-19 vaccine candidates show promising early results, but finish line still far ahead. Professor Adrian Hill of Oxford said the latest data was encouraging.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

New Coronavirus Vaccine Candidate Shows Promise In Early, Limited Trial : Coronavirus Updates Cambridge, Mass.-based Moderna, Inc., is reporting preliminary data suggesting its COVID-19 vaccine is ...

A multidisciplinary team of researchers is the first to show combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against ...

Moderna on Monday announced that it began administering its next generation COVID-19 vaccine candidate in a Phase 1 study. The new candidate, mRNA-1283, can be stored in a refrigerator which could ...

Of the 196 volunteers who caught COVID-19 in the 30,000-person trial, only 11 had been given the vaccine candidate. The fact that Pfizer and Moderna have reported very similar results bodes well ...

Researchers report that a new lipid nanoparticle mRNA coronavirus disease 2019 (COVID-19) vaccine candidate protected 70% of mice expressing the human angiotensin-converting enzyme 2 (ACE2), while ...

The biotech company Moderna released new data Monday morning that strengthens the case for its COVID-19 vaccine. It concludes the vaccine is 94% effective — and strongly protects against serious ...

Their reserves are stocked with Covid-19 vaccines that still possess protective capabilities, but pack a more modest punch, especially against new SARS-CoV-2 variants.